×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OCGN – ocugen, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OCGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
06:45 am
ocgn
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
Low
Report
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
12/19
06:38 am
ocgn
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Medium
Report
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
12/11
07:02 am
ocgn
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
Low
Report
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
11/27
07:19 am
ocgn
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference [Yahoo! Finance]
Medium
Report
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference [Yahoo! Finance]
11/27
07:09 am
ocgn
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
Medium
Report
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
11/20
07:39 am
ocgn
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease [Yahoo! Finance]
Low
Report
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease [Yahoo! Finance]
11/20
07:30 am
ocgn
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
Low
Report
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
11/19
01:08 pm
ocgn
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight [Yahoo! Finance]
Low
Report
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/3
09:50 am
ocgn
Form 8-K Ocugen, Inc. For: Dec 03
Low
Report
Form 8-K Ocugen, Inc. For: Dec 03
12/2
04:16 pm
ocgn
Form 4 Ocugen, Inc. For: Nov 26 Filed by: Fernandes Prabhavathi
Medium
Report
Form 4 Ocugen, Inc. For: Nov 26 Filed by: Fernandes Prabhavathi
11/26
04:55 pm
ocgn
Form 4 Ocugen, Inc. For: Nov 22 Filed by: Castillo Kirsten
Medium
Report
Form 4 Ocugen, Inc. For: Nov 22 Filed by: Castillo Kirsten
11/15
04:18 pm
ocgn
Form 3 Ocugen, Inc. For: Nov 14 Filed by: Ramachandran Ramesh
Medium
Report
Form 3 Ocugen, Inc. For: Nov 14 Filed by: Ramachandran Ramesh
11/15
04:06 pm
ocgn
Form 8-K Ocugen, Inc. For: Nov 14
Medium
Report
Form 8-K Ocugen, Inc. For: Nov 14
11/14
03:26 pm
ocgn
Form 10-Q Ocugen, Inc. For: Sep 30
Low
Report
Form 10-Q Ocugen, Inc. For: Sep 30
11/12
05:00 pm
ocgn
Form SC 13G/A Ocugen, Inc. Filed by: VANGUARD GROUP INC
Medium
Report
Form SC 13G/A Ocugen, Inc. Filed by: VANGUARD GROUP INC
11/12
09:56 am
ocgn
Form 8-K Ocugen, Inc. For: Nov 12
Low
Report
Form 8-K Ocugen, Inc. For: Nov 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/9
Ocugen Announces Share Repurchase Program
32.3%
1/3 Form 8-K Ocugen, Inc. For: Jan 01 31.4%
11/26 Form 8-K Ocugen, Inc. For: Nov 21 19.4%
12/13 Form 3 Ocugen, Inc. For: Sep 27 Filed by: Musunuri Shankar 13.8%
4/7 Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors 12.6%
2/10 Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference 9.7%
5/1 Form 8-K Ocugen, Inc. For: Apr 30 8.0%
11/20 Form 4 Ocugen, Inc. For: Nov 18 Filed by: Zhang Junge 6.5%
10/15 Form 4 Ocugen, Inc. For: Oct 11 Filed by: Zhang Junge 6.3%
12/5 Form 4 Ocugen, Inc. For: Dec 04 Filed by: Zhang Junge 6.1%
1/3 Form 8-K Ocugen, Inc. For: Jan 01 31.4%
11/26 Form 8-K Ocugen, Inc. For: Nov 21 19.4%
12/13 Form 3 Ocugen, Inc. For: Sep 27 Filed by: Musunuri Shankar 13.8%
4/7 Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors 12.6%
2/10 Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference 9.7%
5/1 Form 8-K Ocugen, Inc. For: Apr 30 8.0%
11/20 Form 4 Ocugen, Inc. For: Nov 18 Filed by: Zhang Junge 6.5%
10/15 Form 4 Ocugen, Inc. For: Oct 11 Filed by: Zhang Junge 6.3%
12/5 Form 4 Ocugen, Inc. For: Dec 04 Filed by: Zhang Junge 6.1%
TOP News Decliners
9/30
Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
-59.3%
10/7 Form 8-K Ocugen, Inc. For: Oct 04 -33.7%
3/27 Ocugen Provides Business Update and Full Year 2019 Financial Results -23.1%
11/8 Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights -21.3%
10/2 Form SC 13D/A Ocugen, Inc. Filed by: Wilmslow Estates Ltd -19.4%
11/12 Form 10-Q Ocugen, Inc. For: Sep 30 -18.1%
4/22 Form 8-K Ocugen, Inc. For: Apr 22 -15.0%
12/30 Ocugen (NASDAQ: OCGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.8%
11/8 Form DEF 14A Ocugen, Inc. For: Dec 18 -14.6%
10/9 Form 8-K Ocugen, Inc. For: Oct 08 -13.6%
10/7 Form 8-K Ocugen, Inc. For: Oct 04 -33.7%
3/27 Ocugen Provides Business Update and Full Year 2019 Financial Results -23.1%
11/8 Ocugen Provides Business Update and Third Quarter 2019 Financial Highlights -21.3%
10/2 Form SC 13D/A Ocugen, Inc. Filed by: Wilmslow Estates Ltd -19.4%
11/12 Form 10-Q Ocugen, Inc. For: Sep 30 -18.1%
4/22 Form 8-K Ocugen, Inc. For: Apr 22 -15.0%
12/30 Ocugen (NASDAQ: OCGN) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -14.8%
11/8 Form DEF 14A Ocugen, Inc. For: Dec 18 -14.6%
10/9 Form 8-K Ocugen, Inc. For: Oct 08 -13.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: